Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fludarabine Phosphate in Follicular Lymphoma: NCT07168486 Clinical Landscape Report 2026
28 September 2026
NCT07168486 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD70.CAR NK Cells(Bellicum Pharmaceuticals) in Hodgkin's Lymphoma: NCT07164469 Clinical Landscape Report 2026
28 September 2026
NCT07164469 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EB-104 in Follicular Lymphoma: NCT07168291 Clinical Landscape Report 2026
28 September 2026
NCT07168291 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tunlametinib in NRAS Mutant Melanoma: NCT07170293 Clinical Landscape Report 2026
28 September 2026
NCT07170293 clinical landscape for NRAS Mutant Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fruquintinib in Endometrial Carcinoma: NCT07170982 Clinical Landscape Report 2026
28 September 2026
NCT07170982 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eribulin mesylate in Triple Negative Breast Cancer: NCT07173751 Clinical Landscape Report 2026
28 September 2026
NCT07173751 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
B7-H3 CAR-T(National Cancer Institute) in Wilms Tumor: NCT07172958 Clinical Landscape Report 2026
28 September 2026
NCT07172958 clinical landscape for Wilms Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Advanced Renal Cell Carcinoma: NCT07172386 Clinical Landscape Report 2026
28 September 2026
NCT07172386 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GI-108 in Metastatic Solid Tumor: NCT07172802 Clinical Landscape Report 2026
28 September 2026
NCT07172802 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Synovial sarcoma recurrent: NCT07174427 Clinical Landscape Report 2026
28 September 2026
NCT07174427 clinical landscape for Synovial sarcoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mobocertinib Succinate in Metastatic Renal Cell Carcinoma: NCT07175480 Clinical Landscape Report 2026
28 September 2026
NCT07175480 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab govitecan-hziy in Triple Negative Breast Cancer: NCT07178730 Clinical Landscape Report 2026
28 September 2026
NCT07178730 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.